Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy J Johnson

Showing results (31-40 of 121) with videos related to

Pageof 13
Sort By:
Cancer Research Communications|October 26, 2023
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated TranscriptionMelanie M Frigault, Arushi Mithal, Harvey Wong, et al.
Blood Neoplasia|September 22, 2025
Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibitionRitul Sharma, Chunfen Zhang, Ravi Shah, et al.
Cancers|September 9, 2023
Discovery of VIP236, an αvβ3-Targeted Small-Molecule-Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid TumorsHans-Georg Lerchen, Beatrix Stelte-Ludwig, Melanie Heroult, et al.
Leukemia & Lymphoma|January 15, 2016
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaKami Maddocks, Erin Hertlein, Timothy L Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicitySyed-Rehan A Hussain, Carolyn M Cheney, Amy J Johnson, et al.
Oncotarget|January 19, 2015
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemiaYuh-Ying Yeh, Rong Chen, Joshua Hessler, et al.
Blood|May 4, 2006
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemiaAmy J Johnson, David M Lucas, Natarajan Muthusamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2013
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridolJia Ji, Diane R Mould, Kristie A Blum, et al.
Haematologica|January 25, 2012
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approachDeborah M Stephens, Amy S Ruppert, Kristie Blum, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|December 28, 2018
Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory ModelTravis D Westbrook, Eleshia J Morrison, Kami J Maddocks, et al.
Pageof 13

Showing results (31-40 of 121) with videos related to

Sort By:
Pageof 13
Cancer Research Communications|October 26, 2023
Enitociclib, a Selective CDK9 Inhibitor, Induces Complete Regression of MYC+ Lymphoma by Downregulation of RNA Polymerase II Mediated TranscriptionMelanie M Frigault, Arushi Mithal, Harvey Wong, et al.
Blood Neoplasia|September 22, 2025
Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibitionRitul Sharma, Chunfen Zhang, Ravi Shah, et al.
Cancers|September 9, 2023
Discovery of VIP236, an αvβ3-Targeted Small-Molecule-Drug Conjugate with Neutrophil Elastase-Mediated Activation of 7-Ethyl Camptothecin Payload for Treatment of Solid TumorsHans-Georg Lerchen, Beatrix Stelte-Ludwig, Melanie Heroult, et al.
Leukemia & Lymphoma|January 15, 2016
A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphomaKami Maddocks, Erin Hertlein, Timothy L Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicitySyed-Rehan A Hussain, Carolyn M Cheney, Amy J Johnson, et al.
Oncotarget|January 19, 2015
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemiaYuh-Ying Yeh, Rong Chen, Joshua Hessler, et al.
Blood|May 4, 2006
Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemiaAmy J Johnson, David M Lucas, Natarajan Muthusamy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 10, 2013
A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridolJia Ji, Diane R Mould, Kristie A Blum, et al.
Haematologica|January 25, 2012
Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approachDeborah M Stephens, Amy S Ruppert, Kristie Blum, et al.
Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine|December 28, 2018
Illness Perceptions in Chronic Lymphocytic Leukemia: Testing Leventhal's Self-regulatory ModelTravis D Westbrook, Eleshia J Morrison, Kami J Maddocks, et al.
Pageof 13